Serendip Innovations

Serendip Innovations is a preclinical-stage biotechnology company developing an advanced platform for the stabilization and delivery of biological molecules—including proteins, peptides, and RNA. Through early-stage partnerships with academic groups and biotech/pharmaceutical companies, we offer a co-development model and technology licensing opportunities for applications such as vaccines, cytotoxic payload delivery (ADC-like), and multi-specific therapeutics (e.g, T-cell engagers). Our plant-based platform provides key advantages: low vector immunogenicity, customizable targeting at the cell receptor level, high thermostability, and a fast, cost-efficient production process. What truly differentiates Serendip is the modularity of our core technology, which allows for the precise design of next-generation targeted therapies, along with the scalability and flexibility of our plant-based manufacturing system. As a first application, Serendip and its partners are tackling the complexities of therapeutic cancer vaccines. Our technology has been adapted into a high-performance immunization platform that enhances tumor antigen presentation and stimulates robust anti-tumor immune responses. In a crowded cancer vaccine field, Serendip’s particles distinguish themselves by their ability to selectively target key immune cells and deliver tumor-specific antigens with remarkable precision.